Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 15,501–15,600 of 15,747
CoVacU18-Study: Long-Term Safety of BNT162b2 in Children under 18 Years in GermanyPreprint
Grieshaber, V., Strumann, C., Holzwarth, S., Toepfner, N., von Meißner, W., Konstantopoulos, N., von Poblotzki, M., Hensel, K. O., Moor, M. B., & Chao, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4566186/v1
Recent drugs and vaccines candidates to tackle COVID-19
Mombeni, E. G., YOUSEFI, M., CHEKANI-AZAR, S., Abousenna, M. S., ARMIN, K., SHAVANDI, F., EMAMI, E., & Bahrami, Y. (2020) · Journal of Life Science and Biomedicine · doi:10.51145/jlsb.2020.9
Ehtezazi, T. (2021) · Recent Advances in Drug Delivery and Formulation · doi:10.2174/2772574x12666211122113318
“(modRNA) encoding the SARS-CoV-2 full-length spike, modified by two proline mutations to lock it in the prefusion conformation.(9) The phase II clinical trial indicated that a two-dose regimen (30 μg each dose) of BNT162b2 conferred 95% protection against Covid-19 in”
BackgroundEVENTOS ADVERSOS APÓS A VACINAÇÃO CONTRA A COVID-19 EM LUANDA, ANGOLA
Solari, P. N., Camulça, A., & Brito, I. D. (2025) · Revista científica da Clínica Sagrada Esperança. · doi:10.70360/rccse..v.144
Yoo, H., Pietrasiak, E., & Oh, S. S. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.179124 · Cited by 1
Capella, V. B., & Jääskeläinen, F. D. M. (2023) · Relaciones Internacionales · doi:10.15366/relacionesinternacionales2023.52.008
mRNA Based SARS-CoV-2 Vaccines and Ongoing Researches
Hoşbul, T., Yılmaz, Ü. İ., Aydoğan, C. N., & Şahiner, F. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.20
Mravčík, V., Valachovičová, S. K., & Vobořil, J. (2022) · Central European Journal of Public Health · doi:10.21101/cejph.a7230
“6) in at least 7 days after the second injection (5) in phase 3 clinical trials.”
BackgroundNew, Shorter Small‐Sample Intervals for Vaccine Efficacy
Gasparini, M., Trani, V. D., & Ratta, M. (2026) · Pharmaceutical Statistics · doi:10.1002/pst.70077
Lv, H., Huan, Y. W., Pholcharee, T., Teo, Q. W., Liu, W., Gopal, A. B., Choi, D., Ardagh, M. R., Tan, T. J. C., Sun, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.06.687086
“As exemplified during the COVID-19 pandemic, the mRNA vaccine technology has demonstrated an unprecedented ability to rapidly generate immunogens once an antigen sequence becomes available 70,71 .”
Cowling, T. E., Forbes, H. J., Wing, K., Tazare, J., Schultze, A., Morton, C. E., Bacon, S., MacKenna, B., Walker, A. J., Hulme, W. J., et al. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.19424.1
Duverger, C., Monteil, C., Souyri, V., & Fournier, S. (2024) · American Journal of Infection Control · doi:10.1016/j.ajic.2024.01.004 · Cited by 1
Bartlett, N. W., Bastarache, J. A., Kuebler, W. M., & Schmidt, E. P. (2022) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00352.2022
Duminuco, A., Bulla, A., Rosso, R., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3340893/v1
Monitoramento da presença de anticorpos contra SARS-COV-2
Soares, A. M. A. G., Sardi, S. I., & Campos, G. S. (2024) · Revista de Ciências Médicas e Biológicas · doi:10.9771/cmbio.v23i1.60528
An Ultralong Bovine CDRH3 that Targets a Conserved, Cryptic Epitope on SARS-CoV and SARS-CoV-2Preprint
Burke, M. J., Scott, J. N. F., Minshull, T. C., Stockley, P. G., Calabrese, A. N., & Boyes, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.06.487306
Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation
Deng, Z., Gao, W., Do, J., Aragam, S., Dawd, O., Belthur, M., Shi, D., Kalin, T. V., & Kalinichenko, V. V. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02982-0 · Cited by 2
Precision recruitment for high-risk participants in a COVID-19 research studyPreprint
Mezlini, A. M., Caddigan, E., Shapiro, A. D., et al. (2022) · medRxiv · doi:10.1101/2022.03.03.22271504
Viral Dynamics of the SARS-CoV-2 Omicron Variant in Pediatric Patients: A Prospective Cohort Study
Science, M. E., Orkin, J., Maguire, B. R., Bitnun, A., Bourns, L., Corbeil, A., Johnstone, J., MacDonald, L. M., Schwartz, K. L., Barrett, C. B., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad740
Kealy, L. C., & Good‐Jacobson, K. L. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12548
Evaluation of the effects of vaccination regimes on the transmission dynamics of COVID-19 pandemicPreprint
Nakamoto, I., Zhang, J., Zhuang, W., & Guo, Y. (2022) · medRxiv · doi:10.1101/2022.01.22.22269569
Tsuzuki, S., Akiyama, T., Matsunaga, N., & Ohmagari, N. (2022) · medRxiv · doi:10.1101/2022.07.01.22277144
Analysis of Factors Related to Antibody Titer after BNT162b2 mRNA COVID-19 Vaccine
MARUYAMA, K., Adachi, R., & Sekiya, K. (2022) · Japanese Journal of Infection Prevention and Control · doi:10.4058/jsei.37.248
Kang, H., Lee, J., Jung, J. H., & Oh, E. (2023) · Vaccines · doi:10.3390/vaccines11121803
Literature analysis of the efficacy of COVID-19 vaccinationsPreprint
Hulsen, T. (2022) · medRxiv · doi:10.1101/2022.12.24.22283835
“Comment #3 from Wang [15] stated that the preliminary data do not support the conclusion that this vaccine offers protection against severe COVID-19 illness, since the percentage of COVID-19-positive patients with severe illness was significantly higher in the vaccine group compared to the placebo group.”
ResultInfluentialUtilizing the K18-hACE2 mouse model to develop protective COVID-19 vaccines
Wong, T. Y. (2022) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.11414
Heterologous Vaccination for Preparing COVID-19 Pandemic
Kim, T. H. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.6.450
“3%가 55세를 초과하였기에 고령층에 서도 충분한 효과를 낼 수 있다고 판단하였다[9].”
Modifying SARS-CoV-2 vaccine schedule in Spain: When numbers matters
Díaz‐Menéndez, M., & Malmierca, E. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.01.009
Shirley, D.-A. T. (2022) · The Conversation · doi:10.64628/aai.665c7q47y
Padda, I., & Parmar, M. S. (2021) · NSUWorks (Nova Southeastern University)
Bridging statistics and deep learning: a causal data-fusion framework for epidemic prediction
Papageorgiou, V. Ε., Πετμεζάς, Γ., Georgakis, A., Maglaveras, N., & Tsaklidis, G. M. (2025) · Communications in Statistics - Simulation and Computation · doi:10.1080/03610918.2025.2585395 · Cited by 1
Messenger RNA-encoded reporters for monitoring cellular stress and bioenergetics
Hwang, K. K.-L., Fang, Q., Nizard, C., Bulteau, A., & Woltjen, K. (2026) · Scientific Reports · doi:10.1038/s41598-026-49851-y
das Chagas, R. R., Freitas, H. R., & Cardozo, S. V. (2024) · medRxiv · doi:10.1101/2024.12.03.24318348
Mohapatra, R. K., Seidel, V., Kandi, V., & Rabaan, A. A. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-3603-2
A perspective on targeted LNPs
(1953121), J. B. S., & Spahn, P. N. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115344
Huang, L.-L., Hong, W., Hu, W.-W., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2261201
Lu, X., Hayashi, H., Ishikawa, E., Takeuchi, Y., Dychiao, J. V. T., Hironori Nakagami, A., & Yamasaki, S. (2024) · eLife · doi:10.7554/elife.89999.3
SARS-CoV-2 epidemiology, prevention, risk factors, evaluation, diagnosis, management and vaccines
Al-Nabolsi, M., Alhusein, D., Marchewka, T., Kucera, M., Daher, A., Venida, R., Beydoun, A. K., Surati, R., Deland, A., & Sebastian, M. (2021) · Osteopathic Family Physician · doi:10.33181/13050
Gary, E. N., Tursi, N. J., Hojecki, C. E., Vendramelli, R., Tomirotti, M., Warner, B. M., Livingston, C., Truong, T., Gao, Y., Tiwari, S., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01316-5 · Cited by 1
Gill, P. A., Bradbury, L. R., Wang, A., Hogg, J., Demase, K., McKenzie, J., Fryer, H. A., Geers, D., Zaeck, L. M., Boo, I., et al. (2026) · medRxiv · doi:10.64898/2026.08.28.26359302
AI-guided epitope engineering of a SARS-CoV-2 spike antigen for broad sarbecovirus neutralization
Odainic, A., Vardaxis, I., Ferraz, M., Wiese, K. E., Cornelissen, L. A. H. M., Sharma, A., Stratford, R., Clancy, T., & Bendjama, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1919664
Koizumi, N., Hirai, T., Kano, J., Sato, A., Suzuki, Y., Sasaki, A., Nomura, T., & Utoguchi, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910679
ANALYSIS OF ADVERSE EVENTS AFTER IMMUNIZATION WITH VACCINES AGAINST Sars-Cov-2
Stepanova, H. M., Шевченко, О., & Radziievska, I. (2021) · World Science · doi:10.31435/rsglobal_ws/30112021/7698
Prevalence of hair loss in Egyptian people after covid -19 vaccination.
Ammar, A. M., Shahin, I. M. I., & Mohamed, A. N. (2023) · Al-Azhar International Medical Journal /Al-Azhar International Medical Journal · doi:10.58675/2682-339x.1928
Singh, A. (2021)
Post COVID-19 1 st Dose Vaccination Common Symptoms among SE Asia College StudentsPreprint
Yostyadiananda, N. O., Gunawan, G. R. A., & Wibowo, A. A. (2021) · medRxiv · doi:10.1101/2021.12.21.21268173
Nanomaterials in Therapeutic Application
Talukder, P., Nandi, A., Das, S., Sultana, S., & Sengupta, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898813123125010007
Blake, I., Singleton, R. J., Bruden, D. J. T., Gray, J., Fischer, M., & Keck, J. W. (2026) · International Journal of Circumpolar Health · doi:10.1080/22423982.2026.2706888
“In large randomised, placebo-controlled clinical trials, each vaccine prevented laboratory-confirmed SARS-CoV-2 symptomatic infections [3–5].”
Covid-19: Signs and symptoms related to the feeding behavior
Machado, A. S., Castelo, P. M., Silva, F. C. E., & Lamy, E. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113605
Lou, S., Huang, R., Chen, Z., He, T., Shuai, L., Chen, S., Duan, S., & Wang, H. (2026) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-026-05606-z
Risk factors for low humoral response to BNT-162b2 in hemodialysis patients
Duarte, R. A., Figueiredo, C., Luz, I., et al. (2023) · Clinical Nephrology · doi:10.5414/cn110927
Enhancing RNA Delivery: Practical insights into NeoLNPTM transfection reagent
Chen, X., Wu, Y. X., Liu, L., & Wang, W. (2025) · Methods · doi:10.1016/j.ymeth.2025.05.007
Gemander, N., Neumann, J., Veiga, R., Etienne, I., Prezzemolo, T., Kemlin, D., Pannus, P., Depickère, S., Olislagers, V., Duc, I. V., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01182-1
Greenfield, D. W. (2012) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.210732
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suarez-Alvarez, B. (2021) · Figshare · doi:10.6084/m9.figshare.16786888
Wieske, L., Kummer, L. Y. L., van Dam, K. P. J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19298171
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628929
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suarez-Alvarez, B. (2021) · Figshare · doi:10.6084/m9.figshare.16786882
Parry, H., Bruton, R. K., Stephens, C., Brown, K., Amirthalingam, G., Otter, A., Hallis, B., 左建民, & Moss, P. A. H. (2021) · Figshare · doi:10.6084/m9.figshare.15982342
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suarez-Alvarez, B. (2021) · Figshare · doi:10.6084/m9.figshare.16786891
Additional file 1 of Landscape and selection of vaccine epitopes in SARS-CoV-2
Smith, C. C., Olsen, K. S., Gentry, K. M., Sambade, M., Beck, W. A., Garness, J. A., Entwistle, S., Willis, C., Vensko, S. P., II, Woods, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14782768
Feng, Y., Chen, J., Yao, T., Chang, Y., Li, X., Xing, R., Li, H., Xie, R., Zhang, X., Wei, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17359033
Starrfelt, J., Danielsen, A. S., Buanes, E. A., Juvet, L. K., Lyngstad, T. M., Rø, G., Veneti, L., Watle, S. V., & Meijerink, H. (2022) · Figshare · doi:10.6084/m9.figshare.20786762
Self, W. H., Stewart, T. G., Wheeler, A. P., Atrouni, W. E., Bistran-Hall, A. J., Casey, J. D., Cataldo, V. D., Chappell, J. D., Cohn, C. S., Collins, J. B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253485
Duarte, M. B. O., Leal, F., Argenton, J. L. P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17083862
Mair, M. J., Maj-Hes, A., Nussbaumer-Pröll, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26568304
Lakhlifi, C., Lejeune, F., Rouault, M., Khamassi, M., & Rohaut, B. (2024) · Figshare · doi:10.6084/m9.figshare.26583951
Koh, S. W. C., Liow, Y., Loh, V. W. K., Liew, S. J., Chan, Y.-H., & Young, D. (2022) · Figshare · doi:10.6084/m9.figshare.19603438
Takahashi, K., Samura, O., Hasegawa, A., Okubo, H., Morimoto, K., Horiya, M., Okamoto, A., Ochiai, D., Tanaka, M., Sekiguchi, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22792785
Canti, L., Humblet‐Baron, S., Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., Servais, S., Willems, É., Ehx, G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16864787
Self, W. H., Stewart, T. G., Wheeler, A. P., Atrouni, W. E., Bistran-Hall, A. J., Casey, J. D., Cataldo, V. D., Chappell, J. D., Cohn, C. S., Collins, J. B., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253479
Innocenti, G., Obara, M., Costa, B., Jacobsen, H., Katzmarzyk, M., Čičin‐Šain, L., Kalinke, U., & Galardini, M. (2024) · Figshare · doi:10.6084/m9.figshare.26942604
Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628926
Innocenti, G., Obara, M., Costa, B., Jacobsen, H., Katzmarzyk, M., Čičin‐Šain, L., Kalinke, U., & Galardini, M. (2024) · Figshare · doi:10.6084/m9.figshare.26942580
Iwakawa, S., Azechi, T., Saigo, O., Imai, R., Nakai, A., Koshiba, S., Saito, U., Asakura, K., Sato, K., & Kimura, T. (2024) · Figshare · doi:10.6084/m9.figshare.25341419
Wei, J., Zhang, W., Doherty, M., Wallace, Z. S., Sparks, J. A., Lu, N., Li, X., Zeng, C., Lei, G., & Zhang, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22616996
Innocenti, G., Obara, M., Costa, B., Jacobsen, H., Katzmarzyk, M., Čičin‐Šain, L., Kalinke, U., & Galardini, M. (2024) · Figshare · doi:10.6084/m9.figshare.26942583
Additional file 1 of Modelling the impact of hybrid immunity on future COVID-19 epidemic waves
Le, T. P., Abell, I. R., Conway, E. J., Campbell, P. T., Hogan, A. B., Lydeamore, M., McVernon, J., Mueller, I., Walker, C. R., & Baker, C. M. (2024) · Figshare · doi:10.6084/m9.figshare.26707427
Filippini, F., Giacomelli, M., Bazzani, C., Fredi, M., Semeraro, P., Tomasi, C., Franceschini, F., Caruso, A., Cavazzana, I., & Giagulli, C. (2024) · Figshare · doi:10.6084/m9.figshare.26597237
Takahashi, K., Samura, O., Hasegawa, A., Okubo, H., Morimoto, K., Horiya, M., Okamoto, A., Ochiai, D., Tanaka, M., Sekiguchi, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22792788
Tokumitsu, K., Sugawara, N., Tabuchi, T., & Yasui-Furukori, N. (2024) · Figshare · doi:10.6084/m9.figshare.26019565
Xu, C., He, Z., Lei, W., Chen, L., Shen, D., Xiaofei, W., Xu, D., Xu, Y., & Huang, J. (2022) · Figshare · doi:10.6084/m9.figshare.21532828
Innocenti, G., Obara, M., Costa, B., Jacobsen, H., Katzmarzyk, M., Čičin‐Šain, L., Kalinke, U., & Galardini, M. (2024) · Figshare · doi:10.6084/m9.figshare.26942601
Tan, D. H. S., Chan, A. K., Jüni, P., Tomlinson, G., Daneman, N., Walmsley, S., Muller, M., Fowler, R., Murthy, S., Press, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14266921
Filippini, F., Giacomelli, M., Bazzani, C., Fredi, M., Semeraro, P., Tomasi, C., Franceschini, F., Caruso, A., Cavazzana, I., & Giagulli, C. (2024) · Figshare · doi:10.6084/m9.figshare.26597231
Mehrabi Nejad, M.-M., Shobeiri, P., Dehghanbanadaki, H., Tabary, M., Aryannejad, A., Haji Ghadery, A., Shabani, M., Moosaie, F., SeyedAlinaghi, S., & Rezaei, N. (2022) · Figshare · doi:10.6084/m9.figshare.20452896
Veli, N., Martin, C. A., Woolf, K., Nazareth, J., Pan, D., Al‐Oraibi, A., Baggaley, R. F., Bryant, L., Nellums, L. B., Gray, L. J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303652
Innocenti, G., Obara, M., Costa, B., Jacobsen, H., Katzmarzyk, M., Čičin‐Šain, L., Kalinke, U., & Galardini, M. (2024) · Figshare · doi:10.6084/m9.figshare.26942598
Hamzavi, S. S., Bahrololoom, R., Saeb, S., Marandi, N. H., Hosseini, M., hesam abadi, A. K., & Jamalidoust, M. (2024) · Figshare · doi:10.6084/m9.figshare.26066103
Raynaud, M., Goutaudier, V., Louis, K., Awadhi, S. A., Dubourg, Q., Truchot, A., Brousse, R., Saleh, N., Giarraputo, A., Debiais, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17065819
Sobczak, M., & Pawliczak, R. (2022) · Figshare · doi:10.6084/m9.figshare.20222722
Greenberg, R. S., Ruddy, J. A., Boyarsky, B. J., Werbel, W. A., Garonzik‐Wang, J., Segev, D. L., & Imus, P. H. (2021) · Figshare · doi:10.6084/m9.figshare.17696394
Becker, J. E., Shebl, F. M., Losina, E., Wilson, A. C., Levison, J. H., Donelan, K., Fung, V., Trieu, H. D., Panella, C., Qian, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26738298
Müller, M. K., Volzke, J., Subin, B., Müller, S. C., Sombetzki, M., Reisinger, E. C., & Müller‐Hilke, B. (2022) · Figshare · doi:10.6084/m9.figshare.18666522
Cuapio, A., Boulouis, C., Filipovic, I., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19144918
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suarez-Alvarez, B. (2021) · Figshare · doi:10.6084/m9.figshare.16786885
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.